Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Intensity Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of cancer drugs in the United States. Its lead product candidate includes INT230-6, which is in human clinical studies for the treatment of refractory solid tumors, such as soft tissue sarcoma which is in phase 3 trails; and neoadjuvant and metastatic triple negative breast cancer which is in Phase 2 clinical trials. The company was incorporated in 2012 and is headquartered in Shelton, Connecticut. more
Time Frame | INTS | Sector | S&P500 |
---|---|---|---|
1-Week Return | -8.74% | -2.12% | -3% |
1-Month Return | -36.27% | -3.42% | -0.73% |
3-Month Return | -51.55% | -11.13% | 2.87% |
6-Month Return | -59.74% | -5.74% | 7.17% |
1-Year Return | -68.35% | 3.97% | 25.31% |
3-Year Return | -68.46% | 1.05% | 28.38% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Cost of Revenue | - | - | - | 179.04K | 147.00K | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":82.11,"profit":true}] |
Gross Profit | - | - | - | (179.04K) | (147.00K) | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":-17903700,"profit":false},{"date":"2023-12-31","value":-14700000,"profit":false}] |
Gross Margin | - | - | - | (Infinity%) | (Infinity%) | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":null,"profit":false},{"date":"2023-12-31","value":null,"profit":false}] |
Operating Expenses | 5.68M | 6.22M | 8.01M | 7.55M | 8.32M | [{"date":"2019-12-31","value":68.22,"profit":true},{"date":"2020-12-31","value":74.81,"profit":true},{"date":"2021-12-31","value":96.33,"profit":true},{"date":"2022-12-31","value":90.77,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Income | (5.68M) | (6.22M) | (8.01M) | (7.63M) | (8.32M) | [{"date":"2019-12-31","value":-567553200,"profit":false},{"date":"2020-12-31","value":-622324600,"profit":false},{"date":"2021-12-31","value":-801372200,"profit":false},{"date":"2022-12-31","value":-763202400,"profit":false},{"date":"2023-12-31","value":-831900000,"profit":false}] |
Total Non-Operating Income/Expense | 446.40K | 266.77K | 120.73K | (30.24K) | (2.20M) | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":59.76,"profit":true},{"date":"2021-12-31","value":27.05,"profit":true},{"date":"2022-12-31","value":-6.77,"profit":false},{"date":"2023-12-31","value":-492.83,"profit":false}] |
Pre-Tax Income | (5.38M) | (6.03M) | (7.90M) | (7.58M) | (10.54M) | [{"date":"2019-12-31","value":-537983600,"profit":false},{"date":"2020-12-31","value":-603048000,"profit":false},{"date":"2021-12-31","value":-789560000,"profit":false},{"date":"2022-12-31","value":-758296600,"profit":false},{"date":"2023-12-31","value":-1053800000,"profit":false}] |
Income Taxes | (150.71K) | (74.01K) | (2.61K) | (131.91K) | 1.00 | [{"date":"2019-12-31","value":-15070700,"profit":false},{"date":"2020-12-31","value":-7400900,"profit":false},{"date":"2021-12-31","value":-260900,"profit":false},{"date":"2022-12-31","value":-13190800,"profit":false},{"date":"2023-12-31","value":100,"profit":true}] |
Income After Taxes | (5.23M) | (5.96M) | (7.89M) | (7.45M) | (10.54M) | [{"date":"2019-12-31","value":-522912900,"profit":false},{"date":"2020-12-31","value":-595647100,"profit":false},{"date":"2021-12-31","value":-789299100,"profit":false},{"date":"2022-12-31","value":-745105800,"profit":false},{"date":"2023-12-31","value":-1053800100,"profit":false}] |
Income From Continuous Operations | (5.38M) | (6.03M) | (7.90M) | (7.58M) | (10.54M) | [{"date":"2019-12-31","value":-537983600,"profit":false},{"date":"2020-12-31","value":-603048000,"profit":false},{"date":"2021-12-31","value":-789560000,"profit":false},{"date":"2022-12-31","value":-758296600,"profit":false},{"date":"2023-12-31","value":-1053800000,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (5.23M) | (5.96M) | (7.89M) | (7.45M) | (10.54M) | [{"date":"2019-12-31","value":-522912900,"profit":false},{"date":"2020-12-31","value":-595647100,"profit":false},{"date":"2021-12-31","value":-789299100,"profit":false},{"date":"2022-12-31","value":-745105800,"profit":false},{"date":"2023-12-31","value":-1053800000,"profit":false}] |
EPS (Diluted) | - | - | - | - | (2.88) | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":-288.14,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
INTS | |
---|---|
Cash Ratio | 1.20 |
Current Ratio | 1.63 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
INTS | |
---|---|
ROA (LTM) | -72.74% |
ROE (LTM) | -147.23% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
INTS | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.47 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.53 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
INTS | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 0.00 |
P/B | 10.87 |
Price/FCF | NM |
EV/R | 0.00 |
EV/Ebitda | NM |
Intensity Therapeutics, Inc. Common stock (INTS) share price today is $1.88
Yes, Indians can buy shares of Intensity Therapeutics, Inc. Common stock (INTS) on Vested. To buy Intensity Therapeutics, Inc. Common stock from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in INTS stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Intensity Therapeutics, Inc. Common stock (INTS) via the Vested app. You can start investing in Intensity Therapeutics, Inc. Common stock (INTS) with a minimum investment of $1.
You can invest in shares of Intensity Therapeutics, Inc. Common stock (INTS) via Vested in three simple steps:
The 52-week high price of Intensity Therapeutics, Inc. Common stock (INTS) is $8.79. The 52-week low price of Intensity Therapeutics, Inc. Common stock (INTS) is $1.73.
The price-to-earnings (P/E) ratio of Intensity Therapeutics, Inc. Common stock (INTS) is
The price-to-book (P/B) ratio of Intensity Therapeutics, Inc. Common stock (INTS) is 10.87
The dividend yield of Intensity Therapeutics, Inc. Common stock (INTS) is 0.00%
The market capitalization of Intensity Therapeutics, Inc. Common stock (INTS) is $30.21M
The stock symbol (or ticker) of Intensity Therapeutics, Inc. Common stock is INTS